Patient Surveillance After Cancer Treatment

ISBN-13: 9781603279680 / Angielski / Twarda / 2013 / 538 str.

Frank E Johnson

Opis

'Patient Surveillance After Cancer Treatment' covers the history of cancer patient surveillance after curative-intent treatment. It also examines the rationale and the methodologies used in the past and at present, as well as looking at the methodologies that will probably emerge in the future.

Recenzje

From the reviews:

"This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. ... Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. ... This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent." (Judith G. Abramson, Doody's Book Reviews, September, 2013)

"Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. ... This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library." (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)

Spis treści

1. Overview

David Y. Johnson and Frank E. Johnson

 

2. Introduction to Cancer Surveillance Strategies

Brooke Crawford and David D. Greenberg

 

3. Using Decision Analysis to Model Cancer Surveillance

Kim E.M. van Kessel, Sandra M.E. Geurts, André L.M. Verbeek, and Ewout W. Steyerberg

 

4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment

Craig C. Earle and Jennifer Deevy

 

5. Upper Aerodigestive Tract Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe

Béatrix Barry and Dominique De Raucourt

 

7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan

Torahiko Nakashima, Ryuji Yasumatsu, and Shizuo Komune

 

8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada

Richard W. Nason and James B. Butler

 

9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia

Leigh Delbridge

 

11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan

Ryuji Yasumatsu, Torahiko Nakashima, and Shizuo Komune

 

12. Lung Carcinoma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

13. Lung Carcinoma Surveillance Counterpoint: Australia

Michael Boyer and Kate Mahon

 

14. Lung Carcinoma Surveillance Counterpoint: Japan

Tokujiro Yano and Yoshihiko Maehara

 

15. Lung Carcinoma Surveillance Counterpoint: Canada

Gail Darling, Yee Ung, Peter Ellis, Lorraine Martelli-Reid, and Bill Evans

 

16. Esophagus Carcinoma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

17. Esophagus Carcinoma Surveillance Counterpoint: Australia

Bernard Mark Smithers, Janine M. Thomas, and Bryan H. Burmeister

 

18. Esophagus Carcinoma Surveillance Counterpoint: Japan

Masaru Morita and Yoshihiko Maehara

 

19. Stomach

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

20. Stomach Carcinoma Surveillance Counterpoint: USA

Andrew Coleman and Douglas Tyler

 

21. Stomach Carcinoma Surveillance Counterpoint: Japan

Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara

 

22. Pancreatic Adenocarcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA

Tanios S. Bekaii-Saab

 

24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe

Richard A. Smith, Jane V. Butler, and John P. Neoptolemos

 

25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan

Ken Shirabe and Yoshihiko Maehara

 

26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada

Malcolm J. Moore and Anastasios Stathis

 

27. Liver and Biliary Tract Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe

Michele Colledan

 

29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia

Michael D. Crawford

 

30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan

Akinobu Taketomi and Yoshihiko Maehara

 

31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada

Oliver F. Bathe and Kelly Warren Burak

 

32. Colon and Rectum Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA

Mohamedtaki A. Tejani and Steven J. Cohen

 

34. Colon and Rectum Carcinoma Surveillance Counterpoint: Australia

Toufic El-Khoury, Michael Solomon, and Jane Young

 

35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan

Yasushi Toh and Yoshihisa Sakaguchi

 

36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada

Marko Simunovic

 

37. Anal Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

38. Anal Carcinoma Surveillance Counterpoint: USA

Jonathan M. Hernandez, Erin M. Siegel, Abby Koch, and David Shibata

 

39. Anal Carcinoma Surveillance Counterpoint: Australia

Toufic El-Khoury, Michael Solomon, and Jane Young

 

40. Anal Carcinoma Surveillance Counterpoint: Japan

Yoshihisa Sakaguchi and Yasushi Toh

 

41. Anal Carcinoma Surveillance Counterpoint: Canada

Natasha Press and John Hay

 

42. Soft Tissue Sarcoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

43. Soft Tissue Sarcoma Surveillance Counterpoint: USA

Valeriy Sedov and Janice M. Mehnert

 

44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan

Shuichi Matsuda and Yukihide Iwamoto

 

45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada

Lloyd A. Mack and Vivien H.C. Bramwell

 

46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan

Shuichi Matsuda and Yukihide Iwamoto

 

48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada

Timothy R. Asmis, Joel Werier, and Shailendra Verma

 

49. Cutaneous Melanoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

50. Cutaneous Melanoma Surveillance Counterpoint: USA

Gerald Linette and Lynn A. Cornelius

 

51. Cutaneous Melanoma Surveillance Counterpoint: Australia

Michael A. Henderson

 

52. Cutaneous Melanoma Surveillance Counterpoint: Japan

Yoichi Moroi

 

53. Breast Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

54. Breast Carcinoma Surveillance Counterpoint: USA

Kelli Pettit and Julie A. Margenthaler

 

55. Breast Carcinoma Surveillance Counterpoint: Europe

Stefano Ciatto

 

56. Breast Carcinoma Surveillance Counterpoint: Australia

Andrew J. Spillane and Meagan E. Brennan

 

57. Breast Carcinoma Surveillance Counterpoint: Japan

Eriko Tokunaga and Yoshihiko Maehara

 

58. Endometrial Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

59. Endometrial Cancer Surveillance Counterpoint: USA

Amit Bhate, Eric Donnelly, John Lurain, Julian Schink, and William Small Jr.

 

60. Endometrial Cancer Surveillance Counterpoint: USA

Summer B. Dewdney and Premal H. Thaker

 

61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan

Yousuke Ueoka, Hiroaki Kobayashi, and Norio Wake

 

62. Endometrial Carcinoma Surveillance Counterpoint: Canada

Michael Fung-Kee-Fung and Thomas K. Oliver

 

63. Cervical Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

64. Cervical Carcinoma Surveillance Counterpoint: USA

Joshua P. Kesterson and Shashikant Lele

 

65. Cervical Carcinoma Surveillance Counterpoint: Japan

Kenzo Sonoda, Hiroaki Kobayashi, and Norio Wake

 

66. Cervical Carcinoma Surveillance Counterpoint: Canada

Michael Fung-Kee-Fung and Thomas K. Oliver

 

67. Vaginal and Vulvar Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan

Shinji Ogawa, Hiroaki Kobayashi, and Norio Wake

 

69. Ovarian Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

70. Ovarian Carcinoma Surveillance Counterpoint: USA

Maurie Markman

 

71. Ovarian Cancer Surveillance Counterpoint: Europe

Andy Nordin

 

72. Ovarian Cancer Surveillance Counterpoint: Japan

Hiroaki Kobayashi and Norio Wake

 

73. Renal Carcinoma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

74. Renal Carcinoma Surveillance Counterpoint: Europe

Alessandro Antonelli, Claudio Simeone, and Sergio Cosciani Cunico

 

75. Renal Carcinoma Surveillance Counterpoint: Japan

Masatoshi Eto, Wataru Takahashi, Yoshiaki Kawano, Jiro Honda, Juro Nakanishi, and Yoshihiro Wada

 

76. Renal Carcinoma Surveillance Counterpoint: Canada

Michael Leveridge, Robert Abouassaly, and Michael A.S. Jewett

 

77. Urinary Bladder Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan

Kentaro Kuroiwa

 

79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada

Faysal A. Yafi and Wassim Kassouf

 

80. Prostate Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

81. Prostate Carcinoma Surveillance Counterpoint: USA

Angela Smith and Raj Pruthi

 

82. Prostate Carcinoma Surveillance Counterpoint: USA 

Erik T. Goluboff and Matthew Wosnitzer

 

83. Prostate Carcinoma Surveillance Counterpoint: Europe

Stefano Ciatto

 

84. Prostate Carcinoma Surveillance Counterpoint: Japan

Akira Yokomizo

 

85. Prostate Carcinoma Surveillance Counterpoint: Canada

Andrew Loblaw and Colin Tang

 

86. Testicle Carcinoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

87. Testicle Carcinoma Surveillance Counterpoint: USA

Ian M. Thompson III and Sam S. Chang

 

88. Testicle Carcinoma Surveillance Counterpoint: Australia

Michael Boyer and Kate Mahon

 

89. Testicle Carcinoma Surveillance Counterpoint: Japan

Narihito Seki

 

90. Lymphoma

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

91. Lymphoma Surveillance Counterpoint: USA

Kenneth R. Carson and Nancy L. Bartlett

 

92. Lymphoma Surveillance Counterpoint: Japan

Kenjiro Kamezaki

 

93. Lymphoma (Following Autologous Stem Cell Transplant)

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan

Toshihiro Miyamoto

 

95. Leukemia

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

96. Leukemia Surveillance Counterpoint: USA

Olalekan Oluwole, Susan Greenhut, Bipin N. Savani, and Nishitha Reddy

 

97. Leukemia Surveillance Counterpoint: Japan

Koji Nagafuji

 

98. Multiple Myeloma

Shilpi Wadhwa, David Y. Johnson, and Frank E. Johnson

 

99. Multiple Myeloma Surveillance Counterpoint: USA

Niyati Modi, G. David Roodman, and Suzanne Lentzsch

 

100. Multiple Myeloma Surveillance Counterpoint: Australia

Liane Khoo and Douglas Joshua

 

101. Multiple Myeloma Surveillance Counterpoint: Japan

Katsuto Takenaka

 

102. Multiple Myeloma Surveillance Counterpoint: Canada

Matthew C. Cheung and Kevin R. Imrie

 

103. Glioma of the Central Nervous System

David Y. Johnson, Shilpi Wadhwa, and Frank E. Johnson

 

104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe

Wolfgang Grisold, Stefan Oberndorfer, and Eefje Sizoo

 

105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia

Margot Lehman and Michael Barton

 

106. Glioma of the Central Nervous System Surveillance Counterpoint: Japan

Masahiro Mizoguchi, Koji Yoshimoto, and Tomio Sasaki

O autorze

Dr. Frank E. Johnson, MD

Blurb

Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.

The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.

This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.